Recursion Pharmaceuticals
RXRX
249 hedge funds and large institutions have $2.12B invested in Recursion Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 69 funds opening new positions, 88 increasing their positions, 54 reducing their positions, and 18 closing their positions.
283% more first-time investments, than exits
New positions opened: 69 | Existing positions closed: 18
63% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 54
25% more funds holding
Funds holding: 199 → 249 (+50)
1.83% more ownership
Funds ownership: 100.42% → 102.25% (+1.8%)
3% more capital invested
Capital invested by funds: $2.06B → $2.12B (+$60.2M)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
27% less call options, than puts
Call options by funds: $15.6M | Put options by funds: $21.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$43.8M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
+$12.9M |
| 3 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$12.9M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$10.2M |
| 5 |
JP Morgan Chase
New York
|
+$7.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$35.5M |
| 2 |
State Street
Boston,
Massachusetts
|
-$20M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$18.2M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$11.9M |
| 5 |
DFO
Duquesne Family Office
New York
|
-$8.94M |
RXRX Hedge Fund Activity: Q1 2024 in Review
249 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q1 2024, worth a combined $2.12B — up 2.9% from $2.06B a quarter earlier.
Buyers outnumbered sellers: 69 funds opened new RXRX positions and 18 closed out — a net gain of 51 holders — while 88 added to existing stakes and 54 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $43.8M. The largest seller was Morgan Stanley, cutting an estimated $35.5M.
- 249 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q1 2024, up from 199 in Q4 2023.
- Funds reported $2.12B of Recursion Pharmaceuticals stock for Q1 2024, up 2.9% quarter-over-quarter.
- 69 funds opened new Recursion Pharmaceuticals positions in Q1 2024 and 18 closed out, a net change of +51 holders.
- The largest Recursion Pharmaceuticals buyer in Q1 2024 was ARK Investment Management, an estimated $43.8M added.
- The largest Recursion Pharmaceuticals seller in Q1 2024 was Morgan Stanley, an estimated $35.5M sold.
Based on aggregated 13F filings for Q1 2024.